Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

A tissue-based draft map of the murine MHC class I immunopeptidome.

Schuster H, Shao W, Weiss T, Pedrioli PGA, Roth P, Weller M, Campbell DS, Deutsch EW, Moritz RL, Planz O, Rammensee HG, Aebersold R, Caron E.

Sci Data. 2018 Aug 7;5:180157. doi: 10.1038/sdata.2018.157.

2.

The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression.

Schräder T, Dudek SE, Schreiber A, Ehrhardt C, Planz O, Ludwig S.

Antiviral Res. 2018 Sep;157:80-92. doi: 10.1016/j.antiviral.2018.07.006. Epub 2018 Jul 7.

3.

Metabolic conversion of CI-1040 turns a cellular MEK-inhibitor into an antibacterial compound.

Bruchhagen C, Jarick M, Mewis C, Hertlein T, Niemann S, Ohlsen K, Peters G, Planz O, Ludwig S, Ehrhardt C.

Sci Rep. 2018 Jun 14;8(1):9114. doi: 10.1038/s41598-018-27445-7.

4.

Targeting intracellular signaling as an antiviral strategy: aerosolized LASAG for the treatment of influenza in hospitalized patients.

Scheuch G, Canisius S, Nocker K, Hofmann T, Naumann R, Pleschka S, Ludwig S, Welte T, Planz O.

Emerg Microbes Infect. 2018 Mar 7;7(1):21. doi: 10.1038/s41426-018-0023-3.

5.

Pharmacodynamics, Pharmacokinetics, and Antiviral Activity of BAY 81-8781, a Novel NF-κB Inhibiting Anti-influenza Drug.

Droebner K, Haasbach E, Dudek SE, Scheuch G, Nocker K, Canisius S, Ehrhardt C, von Degenfeld G, Ludwig S, Planz O.

Front Microbiol. 2017 Nov 2;8:2130. doi: 10.3389/fmicb.2017.02130. eCollection 2017.

6.

Phenol-Soluble Modulin Peptides Contribute to Influenza A Virus-Associated Staphylococcus aureus Pneumonia.

Bloes DA, Haasbach E, Hartmayer C, Hertlein T, Klingel K, Kretschmer D, Planz O, Peschel A.

Infect Immun. 2017 Nov 17;85(12). pii: e00620-17. doi: 10.1128/IAI.00620-17. Print 2017 Dec.

7.

The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo.

Haasbach E, Müller C, Ehrhardt C, Schreiber A, Pleschka S, Ludwig S, Planz O.

Antiviral Res. 2017 Jun;142:178-184. doi: 10.1016/j.antiviral.2017.03.024. Epub 2017 Apr 2.

8.

Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy.

Barth SM, Schreitmüller CM, Proehl F, Oehl K, Lumpp LM, Kowalewski DJ, Di Marco M, Sturm T, Backert L, Schuster H, Stevanović S, Rammensee HG, Planz O.

PLoS One. 2016 Nov 28;11(11):e0167017. doi: 10.1371/journal.pone.0167017. eCollection 2016.

9.

Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.

Muhammad S, Planz O, Schwaninger M.

Cerebrovasc Dis Extra. 2016;6(2):50-9. doi: 10.1159/000447750. Epub 2016 Aug 25.

10.

Cytotoxic T cell vaccination with PLGA microspheres interferes with influenza A virus replication in the lung and suppresses the infectious disease.

Herrmann VL, Hartmayer C, Planz O, Groettrup M.

J Control Release. 2015 Oct 28;216:121-31. doi: 10.1016/j.jconrel.2015.08.019. Epub 2015 Aug 12.

PMID:
26276509
11.

Antiviral activity of Ladania067, an extract from wild black currant leaves against influenza A virus in vitro and in vivo.

Haasbach E, Hartmayer C, Hettler A, Sarnecka A, Wulle U, Ehrhardt C, Ludwig S, Planz O.

Front Microbiol. 2014 Apr 22;5:171. doi: 10.3389/fmicb.2014.00171. eCollection 2014.

12.

The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus.

Haasbach E, Reiling SJ, Ehrhardt C, Droebner K, Rückle A, Hrincius ER, Leban J, Strobl S, Vitt D, Ludwig S, Planz O.

Antiviral Res. 2013 Sep;99(3):336-44. doi: 10.1016/j.antiviral.2013.06.008. Epub 2013 Jun 28.

PMID:
23811282
13.

A plant extract of Ribes nigrum folium possesses anti-influenza virus activity in vitro and in vivo by preventing virus entry to host cells.

Ehrhardt C, Dudek SE, Holzberg M, Urban S, Hrincius ER, Haasbach E, Seyer R, Lapuse J, Planz O, Ludwig S.

PLoS One. 2013 May 23;8(5):e63657. doi: 10.1371/journal.pone.0063657. Print 2013.

14.

Development of cellular signaling pathway inhibitors as new antivirals against influenza.

Planz O.

Antiviral Res. 2013 Jun;98(3):457-68. doi: 10.1016/j.antiviral.2013.04.008. Epub 2013 Apr 16. Review.

PMID:
23603495
15.

Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro.

Haasbach E, Hartmayer C, Planz O.

Antiviral Res. 2013 May;98(2):319-24. doi: 10.1016/j.antiviral.2013.03.006. Epub 2013 Mar 20.

PMID:
23523553
16.

The NF-κB inhibitor SC75741 efficiently blocks influenza virus propagation and confers a high barrier for development of viral resistance.

Ehrhardt C, Rückle A, Hrincius ER, Haasbach E, Anhlan D, Ahmann K, Banning C, Reiling SJ, Kühn J, Strobl S, Vitt D, Leban J, Planz O, Ludwig S.

Cell Microbiol. 2013 Jul;15(7):1198-211. doi: 10.1111/cmi.12108. Epub 2013 Feb 5.

PMID:
23320394
17.

PAR1 contributes to influenza A virus pathogenicity in mice.

Khoufache K, Berri F, Nacken W, Vogel AB, Delenne M, Camerer E, Coughlin SR, Carmeliet P, Lina B, Rimmelzwaan GF, Planz O, Ludwig S, Riteau B.

J Clin Invest. 2013 Jan;123(1):206-14. doi: 10.1172/JCI61667. Epub 2012 Dec 3.

18.

The NS1 protein of influenza A virus blocks RIG-I-mediated activation of the noncanonical NF-κB pathway and p52/RelB-dependent gene expression in lung epithelial cells.

Rückle A, Haasbach E, Julkunen I, Planz O, Ehrhardt C, Ludwig S.

J Virol. 2012 Sep;86(18):10211-7. doi: 10.1128/JVI.00323-12. Epub 2012 Jul 11.

19.

The adaptor protein FHL2 enhances the cellular innate immune response to influenza A virus infection.

Nordhoff C, Hillesheim A, Walter BM, Haasbach E, Planz O, Ehrhardt C, Ludwig S, Wixler V.

Cell Microbiol. 2012 Jul;14(7):1135-47. doi: 10.1111/j.1462-5822.2012.01787.x. Epub 2012 Apr 12.

PMID:
22417706
20.

Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo.

Droebner K, Pleschka S, Ludwig S, Planz O.

Antiviral Res. 2011 Nov;92(2):195-203. doi: 10.1016/j.antiviral.2011.08.002. Epub 2011 Aug 11.

PMID:
21854809
21.

Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.

Haasbach E, Pauli EK, Spranger R, Mitzner D, Schubert U, Kircheis R, Planz O.

Antiviral Res. 2011 Sep;91(3):304-13. doi: 10.1016/j.antiviral.2011.07.006. Epub 2011 Jul 13.

PMID:
21777621
22.

Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo.

Pinto R, Herold S, Cakarova L, Hoegner K, Lohmeyer J, Planz O, Pleschka S.

Antiviral Res. 2011 Oct;92(1):45-56. doi: 10.1016/j.antiviral.2011.05.009. Epub 2011 May 27.

PMID:
21641936
23.

Low-dose interferon Type I treatment is effective against H5N1 and swine-origin H1N1 influenza A viruses in vitro and in vivo.

Haasbach E, Droebner K, Vogel AB, Planz O.

J Interferon Cytokine Res. 2011 Jun;31(6):515-25. doi: 10.1089/jir.2010.0071. Epub 2011 Feb 16.

PMID:
21323570
24.

Influenza virus H5N1 hemagglutinin (HA) T-cell epitope conjugates: design, synthesis and immunogenicity.

Skarlas T, Zevgiti S, Droebner K, Panou-Pomonis E, Planz O, Sakarellos-Daitsiotis M.

J Pept Sci. 2011 Mar;17(3):226-32. doi: 10.1002/psc.1320. Epub 2010 Nov 30.

PMID:
21308879
25.

Influenza virus infection aggravates stroke outcome.

Muhammad S, Haasbach E, Kotchourko M, Strigli A, Krenz A, Ridder DA, Vogel AB, Marti HH, Al-Abed Y, Planz O, Schwaninger M.

Stroke. 2011 Mar;42(3):783-91. doi: 10.1161/STROKEAHA.110.596783. Epub 2011 Feb 3.

PMID:
21293018
26.

Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV).

Sipo I, Knauf M, Fechner H, Poller W, Planz O, Kurth R, Norley S.

Vaccine. 2011 Feb 11;29(8):1690-9. doi: 10.1016/j.vaccine.2010.12.037. Epub 2010 Dec 30.

PMID:
21195079
27.

Highly pathogenic influenza virus infection of the thymus interferes with T lymphocyte development.

Vogel AB, Haasbach E, Reiling SJ, Droebner K, Klingel K, Planz O.

J Immunol. 2010 Oct 15;185(8):4824-34. doi: 10.4049/jimmunol.0903631. Epub 2010 Sep 22.

28.

The alternative NF-kappaB signalling pathway is a prerequisite for an appropriate immune response against lymphocytic choriomeningitis virus infection.

Droebner K, Klein B, Paxian S, Schmid R, Stitz L, Planz O.

Viral Immunol. 2010 Jun;23(3):295-308. doi: 10.1089/vim.2009.0101.

PMID:
20565293
29.

The NS segment of an H5N1 highly pathogenic avian influenza virus (HPAIV) is sufficient to alter replication efficiency, cell tropism, and host range of an H7N1 HPAIV.

Ma W, Brenner D, Wang Z, Dauber B, Ehrhardt C, Högner K, Herold S, Ludwig S, Wolff T, Yu K, Richt JA, Planz O, Pleschka S.

J Virol. 2010 Feb;84(4):2122-33. doi: 10.1128/JVI.01668-09. Epub 2009 Dec 9.

30.

Spread of infection and lymphocyte depletion in mice depends on polymerase of influenza virus.

Gabriel G, Klingel K, Planz O, Bier K, Herwig A, Sauter M, Klenk HD.

Am J Pathol. 2009 Sep;175(3):1178-86. doi: 10.2353/ajpath.2009.090339. Epub 2009 Aug 21.

31.

Borna disease virus: a unique pathogen and its interaction with intracellular signalling pathways.

Planz O, Pleschka S, Wolff T.

Cell Microbiol. 2009 Jun;11(6):872-9. doi: 10.1111/j.1462-5822.2009.01310.x. Epub 2009 Mar 12. Review.

PMID:
19290912
32.

Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain.

Droebner K, Haasbach E, Fuchs C, Weinzierl AO, Stevanovic S, Büttner M, Planz O.

Vaccine. 2008 Dec 9;26(52):6965-74. doi: 10.1016/j.vaccine.2008.09.051. Epub 2008 Oct 9.

PMID:
18848593
33.

Role of hypercytokinemia in NF-kappaB p50-deficient mice after H5N1 influenza A virus infection.

Droebner K, Reiling SJ, Planz O.

J Virol. 2008 Nov;82(22):11461-6. doi: 10.1128/JVI.01071-08. Epub 2008 Sep 3.

34.

Influenza viruses and the NF-kappaB signaling pathway - towards a novel concept of antiviral therapy.

Ludwig S, Planz O.

Biol Chem. 2008 Oct;389(10):1307-12. doi: 10.1515/BC.2008.148. Review.

PMID:
18713017
35.

Alteration of NF-kappaB activity leads to mitochondrial apoptosis after infection with pathological prion protein.

Bourteele S, Oesterle K, Weinzierl AO, Paxian S, Riemann M, Schmid RM, Planz O.

Cell Microbiol. 2007 Sep;9(9):2202-17. Epub 2007 Jun 15.

36.

CYSTUS052, a polyphenol-rich plant extract, exerts anti-influenza virus activity in mice.

Droebner K, Ehrhardt C, Poetter A, Ludwig S, Planz O.

Antiviral Res. 2007 Oct;76(1):1-10. Epub 2007 May 15.

PMID:
17573133
37.

A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance.

Ehrhardt C, Hrincius ER, Korte V, Mazur I, Droebner K, Poetter A, Dreschers S, Schmolke M, Planz O, Ludwig S.

Antiviral Res. 2007 Oct;76(1):38-47. Epub 2007 Jun 4.

PMID:
17572513
38.

Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity.

Mazur I, Wurzer WJ, Ehrhardt C, Pleschka S, Puthavathana P, Silberzahn T, Wolff T, Planz O, Ludwig S.

Cell Microbiol. 2007 Jul;9(7):1683-94. Epub 2007 Feb 23.

PMID:
17324159
39.

Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses.

Ehrhardt C, Wolff T, Pleschka S, Planz O, Beermann W, Bode JG, Schmolke M, Ludwig S.

J Virol. 2007 Apr;81(7):3058-67. Epub 2007 Jan 17.

40.

Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence.

Ehrhardt C, Marjuki H, Wolff T, Nürnberg B, Planz O, Pleschka S, Ludwig S.

Cell Microbiol. 2006 Aug;8(8):1336-48.

PMID:
16882036
41.

Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase Calpha-mediated activation of ERK signaling.

Marjuki H, Alam MI, Ehrhardt C, Wagner R, Planz O, Klenk HD, Ludwig S, Pleschka S.

J Biol Chem. 2006 Jun 16;281(24):16707-15. Epub 2006 Apr 11.

42.

[Influenza viruses and intracellular signalling pathways].

Planz O.

Berl Munch Tierarztl Wochenschr. 2006 Mar-Apr;119(3-4):101-11. Review. German.

PMID:
16573200
43.

Ringing the alarm bells: signalling and apoptosis in influenza virus infected cells.

Ludwig S, Pleschka S, Planz O, Wolff T.

Cell Microbiol. 2006 Mar;8(3):375-86. Review.

PMID:
16469051
44.

The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host.

Gabriel G, Dauber B, Wolff T, Planz O, Klenk HD, Stech J.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18590-5. Epub 2005 Dec 8.

45.

The negative regulator of Borna disease virus polymerase is a non-structural protein.

Schwardt M, Mayer D, Frank R, Schneider U, Eickmann M, Planz O, Wolff T, Schwemmle M.

J Gen Virol. 2005 Nov;86(Pt 11):3163-9.

PMID:
16227240
46.

Viral targeting of the interferon-{beta}-inducing Traf family member-associated NF-{kappa}B activator (TANK)-binding kinase-1.

Unterstab G, Ludwig S, Anton A, Planz O, Dauber B, Krappmann D, Heins G, Ehrhardt C, Wolff T.

Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13640-5. Epub 2005 Sep 9.

47.

Constitutive activation of the transcription factor NF-kappaB results in impaired borna disease virus replication.

Bourteele S, Oesterle K, Pleschka S, Unterstab G, Ehrhardt C, Wolff T, Ludwig S, Planz O.

J Virol. 2005 May;79(10):6043-51.

49.

Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice.

Olschläger V, Pleschka S, Fischer T, Rziha HJ, Wurzer W, Stitz L, Rapp UR, Ludwig S, Planz O.

Oncogene. 2004 Aug 26;23(39):6639-46.

PMID:
15235583
50.

Supplemental Content

Support Center